V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016780 | 160013434 | null | 71.6 | Curative (C) | 2016-04-08 | 2016-04-15 | Cyclophosphamide + Vincristine | 02 | N | OLAPARIB | 100363669 |
| 160016782 | 160013435 | 1.6 | 72.7 | Neo-adjuvant (N) | 2018-06-07 | 2018-06-07 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | TEMOZOLOMIDE | 100824888 |
| 160016784 | 160013436 | 1.68 | 74.7 | null | null | null | Dinutuximab Beta | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101548082 |
| 160016792 | 160013437 | 1.07 | 80 | Curative (C) | 2016-05-19 | 2016-07-21 | Capecitabine | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101416809 |
| 160016795 | 160013438 | 1.73 | 74 | null | 2016-12-11 | 2017-06-25 | Cisplatin + Etoposide po | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100985487 |
| 160016802 | 160013440 | 1.63 | 90.8 | null | 2018-03-20 | 2018-04-17 | IPILIMUMAB + NIVOLUMAB | 02 | null | NOT MATCHED | 101818931 |
| 160016803 | 160013441 | null | null | Palliative (P) | 2018-03-29 | 2018-10-01 | CABOZANTINIB | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101513425 |
| 160016809 | 160013443 | 1.71 | 43.5 | null | 2020-07-15 | 2021-01-25 | EW EuroEwing 2012 Arm A/B Zol Acid | 02 | N | DACARBAZINE | 100670122 |
| 160016810 | 160013444 | null | 114.6 | Palliative (P) | 2016-06-18 | 2017-11-18 | VAC | N | N | STS RHABDO RMS 2005 VIN CYCLO | 101402124 |
| 160016811 | 160013445 | 1.64 | 54 | null | null | null | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100428216 |
| 160016819 | 160013447 | 1.69 | 60.3 | Palliative (P) | 2017-12-27 | 2018-02-25 | PEMBROLIZUMAB | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101758856 |
| 160016821 | 160013448 | 1.62 | 85 | Palliative (P) | 2020-08-08 | 2020-08-28 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | N | CYCLOPHOSPHAMIDE | 100993875 |
| 160016822 | 160013449 | 1.84 | 19.3 | Adjuvant (A) | 2019-02-09 | 2019-02-28 | Gemcitabine weekly | 1 | Y | STS RHABDO RMS 2005 VIN CYCLO | 100360392 |
| 160016826 | 160013450 | 1.54 | 63.9 | null | 2019-07-04 | 2019-07-10 | IRINOTECAN + VINCRISTINE | 02 | null | EW EUROEWING 2012 ARM A VAC | 101137397 |
| 160016827 | 160013451 | 1.64 | 74.7 | null | 2018-02-06 | 2018-06-05 | Ifosfamide | 02 | null | NB HRNBL-1 ISOTRETINOIN | 100174492 |
| 160016830 | 160013452 | 0 | 88 | null | 2019-09-09 | 2019-09-12 | Cyclophosphamide oral | 02 | null | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101372821 |
| 160016834 | 160013453 | 0 | 54.8 | null | 2017-10-08 | 2017-10-08 | EW EuroEwing 2012 Arm B VDC | null | null | EW EUROEWING 2012 ARM B VC | 101549790 |
| 160016838 | 160013454 | 1.58 | 99 | Palliative (P) | 2016-07-08 | 2016-08-22 | Niraparib | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100101467 |
| 160016841 | 160013455 | 0 | 13.9 | null | 2018-07-18 | 2019-02-06 | ETOPOSIDE | 02 | null | NB HRNBL-1 BUMEL MAT | 101515893 |
| 160016844 | 160013456 | 1.68 | 67.4 | Palliative (P) | 2016-04-15 | 2016-05-04 | EW Rel rEECur Irinotecan/Temozolomide | Y | N | DACARBAZINE | 100517306 |
| 160016845 | 160013457 | 0 | 16.8 | Curative (C) | 2016-01-15 | 2017-05-22 | PROMISE-MESO TRIAL | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101401805 |
| 160016847 | 160013458 | 1.69 | 82.2 | Disease modification (D) | 2018-06-19 | 2018-06-20 | EW EuroEwing 2012 Arm A VIDE | N | N | POMALIDOMIDE | 101440899 |
| 160016852 | 160013460 | 1.9 | 39.1 | null | 2016-01-17 | 2016-08-18 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | TRIAL | 100332645 |
| 160016855 | 160013461 | 1.84 | 18.2 | null | 2015-01-31 | 2015-02-05 | DACARBAZINE + GEMCITABINE | 02 | null | DACARBAZINE | 101297903 |
| 160016864 | 160013462 | null | null | Curative (C) | 2018-01-15 | 2018-01-20 | Doxorubicin + Ifosfamide | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100026642 |
| 160016865 | 160013463 | 0 | 35.1 | Curative (C) | 2018-09-04 | 2018-09-04 | Olaratumab | 02 | N | OLARATUMAB | 100784015 |
| 160016867 | 160013464 | 0 | 94 | null | 2018-06-13 | 2018-06-26 | VAI (Ifos 3g/m2) | 01 | null | TRIAL | 100405415 |
| 160016868 | 160013465 | 1.55 | 98.1 | null | 2018-09-25 | 2019-11-23 | EW EuroEwing 2012 Arm B IE | null | null | ETOPOSIDE | 101197738 |
| 160016869 | 160013466 | 1.79 | 9 | Curative (C) | 2018-08-21 | 2019-01-28 | IVA | null | null | IRINOTECAN + TEMOZOLOMIDE | 100954955 |
| 160016873 | 160013467 | 1.82 | 65.5 | Neo-adjuvant (N) | 2019-04-28 | 2019-05-15 | null | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100042010 |
| 160016877 | 160013468 | 1.68 | 54.2 | Palliative (P) | 2017-05-14 | 2017-11-01 | Doxorubicin + Ifosfamide | 02 | N | CARBOPLATIN + VINORELBINE | 100841815 |
| 160016881 | 160013469 | 1.71 | 56.1 | Curative (C) | 2018-04-09 | 2019-04-03 | Rucaparib | null | null | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100221303 |
| 160016883 | 160013470 | 1.64 | 69 | Palliative (P) | 2016-05-16 | 2016-11-07 | GEMCITABINE | 02 | N | OLAPARIB | 101350829 |
| 160016884 | 160013471 | null | 17.1 | Curative (C) | 2018-08-30 | 2018-10-16 | Vincristine (weekly) | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101006458 |
| 160016885 | 160013472 | 1.76 | 18 | Palliative (P) | 2018-03-28 | 2018-09-01 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101028116 |
| 160016887 | 160013473 | 1.68 | 73.6 | Palliative (P) | 2016-09-10 | 2016-10-25 | Trial Unspecified | 02 | N | NOT MATCHED | 100948053 |
| 160016889 | 160013474 | null | 78.7 | Curative (C) | 2016-09-15 | 2016-10-19 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | EW EUROEWING 2012 ARM B IE | 100828540 |
| 160016893 | 160013475 | 1.78 | 82.4 | Palliative (P) | 2017-07-05 | 2017-07-05 | Doxorubicin + Ifosfamide | 02 | N | EW EUROEWING 2012 ARM B VDC/IE | 100280433 |
| 160016895 | 160013476 | 0 | 87 | Palliative (P) | 2017-09-23 | 2017-11-15 | EW EuroEwing 2012 Arm B VDC | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100586589 |
| 160016901 | 160013477 | 1.61 | 78.5 | null | 2022-03-08 | 2022-03-23 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101762420 |
| 160016906 | 160013478 | 1.69 | 74.1 | Palliative (P) | null | 2018-11-08 | Doxorubicin + Ifosfamide | 02 | N | IVA | 101145806 |
| 160016913 | 160013479 | 1.88 | 115.65 | Palliative (P) | 2013-09-21 | 2014-01-21 | VINCRISTINE | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101688532 |
| 160016914 | 160013480 | 0 | 10.8 | null | 2016-10-08 | 2017-07-20 | Bevacizumab+Carbo+Pacliaxel | 02 | null | EW EUROEWING 2012 ARM B IE | 101839026 |
| 160016915 | 160013481 | null | 82.9 | null | 2022-03-09 | 2022-04-25 | DHAP | 02 | null | OLARATUMAB | 101636097 |
| 160016921 | 160013482 | 0 | 78.1 | Palliative (P) | 2020-06-02 | 2020-07-23 | DACARBAZINE + GEMCITABINE | N | N | IFOSFAMIDE | 100601969 |
| 160016923 | 160013483 | 0 | 113.8 | Palliative (P) | 2014-12-13 | 2016-06-27 | IPM | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100612536 |
| 160016928 | 160013484 | 1.88 | 66.7 | 03 | 2016-09-08 | 2016-09-14 | CONFIRM TRIAL | 02 | N | EURO-EWING | 100225062 |
| 160016932 | 160013485 | null | null | null | 2017-08-10 | 2018-01-21 | STS Rhabdo RMS 2005 Vin Cyclo | N | null | PEMBROLIZUMAB | 100082815 |
| 160016938 | 160013486 | 1.6 | 103 | Palliative (P) | 2022-02-14 | 2022-02-21 | Ifosfamide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100994658 |
| 160016940 | 160013487 | 1.62 | 97.5 | 03 | 2019-05-15 | 2019-05-15 | NB HRNBL-1 COJEC Ind COURSE C | N | N | NB HRNBL-1 ISOTRETINOIN | 100527877 |